Results 51 to 60 of about 40,259 (213)
Considerations for drug trials in hypertrophic cardiomyopathy
ESC Heart Failure, Volume 12, Issue 2, Page 1095-1112, April 2025.Abstract Hypertrophic cardiomyopathy (HCM) is a heterogeneous condition with potentially serious manifestations. Management has traditionally comprised therapies to palliate symptoms and implantable cardioverter‐defibrillators to prevent sudden cardiac death. The need for disease‐modifying therapies has been recognized for decades.
John P. Farrant +17 more
wiley +1 more source
A One Health Approach to Hypertrophic Cardiomyopathy. [PDF]
, 2017 Hypertrophic cardiomyopathy (HCM) is the most common inherited cardiac disease in humans and results in significant morbidity and mortality. Research over the past 25 years has contributed enormous insight into this inherited disease particularly in the ...
Stern, Joshua A, Ueda, Yu
core +1 more source
Cardiac Calcitropes, Myotropes, and Mitotropes: JACC Review Topic of the Week. [PDF]
, 2019 The term "inotrope" is familiar and intimately connected with pharmaceuticals clinically used for treatment of low cardiac output with cardiogenic shock.
Adams, KF +7 more
core +2 more sources
ESC Heart Failure, Volume 12, Issue 2, Page 1386-1397, April 2025.Sequeira et al. reveal how the glucagon‐like peptide‐1 receptor agonist (GLP‐1‐RA) semaglutide restores cardiomyocyte function in rats subjected to a high‐fat/high‐fructose diet (HFD). Employing fluorescence‐ and patch‐clamp technology in isolated cardiac myocytes, they demonstrate that semaglutide reverses HFD‐induced activation of L‐type calcium ...
Vasco Sequeira +12 more
wiley +1 more source
The myosin activator omecamtiv mecarbil: a promising new inotropic agent [PDF]
, 2018 K
Nánási, Péter Pál ifj. +2 more
core +1 more source
A First in Human Study of the Selective Cardiac Myosin Inhibitor, CK-3773274 [PDF]
Journal of Cardiac Failure, 2019 Introduction Hypercontractility of the cardiac sarcomere appears to underlie pathological hypertrophy and fibrosis in select genetic hypertrophic cardiomyopathies (HCM). CK-3773274 (CK-274) decreases systolic function in preclinical models by directly binding to the cardiac myosin motor domain and inhibiting the myosin ATPase, stabilizing the motor in
Laura A. Robertson +6 more
openaire +1 more source
Decreased soluble guanylate cyclase contributes to cardiac dysfunction induced by chronic doxorubicin treatment in mice [PDF]
, 2017 Aims: The use of doxorubicin, a potent chemotherapeutic agent, is limited by cardiotoxicity. We tested the hypothesis that decreased soluble guanylate cyclase (sGC) enzyme activity contributes to the development of doxorubicin-induced cardiotoxicity ...
Allen, Kaitlin +15 more
core +1 more source
iMeta, EarlyView.We utilized single‐cell RNA sequencing (scRNA‐seq) to investigate cellular heterogeneity and signaling networks in aortic dissection (AD) tissues compared to adjacent normal tissues. The analysis identified five smooth muscle cell (SMC) subtypes, with SMC2 linked to fibrosis and SMC3 associated with inflammation.
Liang Shao +12 more
wiley +1 more source
Preferential Myosin Heavy Chain Isoform B Expression May Contribute to the Faster Velocity of Contraction in Veins versus Arteries [PDF]
, 2007 Smooth muscle myosin heavy chains occur in 2 isoforms, SMA (slow) and SMB (fast). We hypothesized that the SMB isoform is predominant in the faster-contracting rat vena cava compared to thoracic aorta.
Eddinger, Thomas +8 more
core +1 more source
Epigenomes in Cardiovascular Disease. [PDF]
, 2018 If unifying principles could be revealed for how the same genome encodes different eukaryotic cells and for how genetic variability and environmental input are integrated to impact cardiovascular health, grand challenges in basic cell biology and ...
McKinsey TA +4 more
core +1 more source